| Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | coronary heart disease type 2 diabetes
 cancer (endometrial, breast, and colon)
 hypertension
 dyslipidemia
 stroke
 liver and gallbladder disease
 sleep apnea and respiratory problems
 osteoarthritis
 gynecological problems
 |  | Definition 
 
        | health consequences of obesity |  | 
        |  | 
        
        | Term 
 
        | abdominal obesity, given as waist circumference:  women > 35 in, men > 40 in triglycerides:  > 150 mg/dL
 HDL:  women < 50 mg/dL, men < 40 mg/dL
 blood pressure:  >/= 130/85 mmHg
 fasting glucose:  >/= 110 mg/dL
 |  | Definition 
 
        | metabolic syndrome:  a cluster of risk factors that increase risk of cardiovascular disease what are the risk factors and their defining levels?
 |  | 
        |  | 
        
        | Term 
 
        | genetics environmental
 physiological (neuro)
 |  | Definition 
 
        | what causes can contribute to obesity/overweight? |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | what is the primary neuropeptide controlling the hedonic aspects processed in the limbic area of the brain? |  | 
        |  | 
        
        | Term 
 
        | REDUCE body weight:  5-10%; studies show that even modest weight reduction of 5-10% can greatly decrease risk of obesity-associated risk factors MAINTAIN lower body weight long term
 PREVENT further weight gain
 |  | Definition 
 
        | goals of obesity treatments |  | 
        |  | 
        
        | Term 
 
        | increased secretion/reuptake inhibitor of NE ADRs:  abuse potential, sleepiness
 contraindications: CVD, HTN, hyperthyroidism, MOAi
 |  | Definition 
 
        | MOA, side effects, and contraindications of phenterimine (Adipex) |  | 
        |  | 
        
        | Term 
 
        | MOA:  increase secretion/reuptake inhibitor of NE ADRs: abuse potential, sleepiness
 CI:  CVD, HTN, hyperthyroidism, MOAi
 |  | Definition 
 
        | MOA, side effects, and contraindications of diethylpropion(Tenuate) |  | 
        |  | 
        
        | Term 
 
        | BMI >/= 30 BMI 27-29.9 with risk factors and comorbidities:  HTN, dyslipidemia, CHD, DM2, sleep apnea
 lack of RCT showing one agent is more effective vs. another: patient preference, comorbidities, cost
 to day no long term data on morbidity and mortality end points
 |  | Definition 
 
        | when is medication indicated for obesity? |  | 
        |  | 
        
        | Term 
 
        | vitamin B1 (thiamine) deficiency: vitamin B12
 iron:  most iron absorption occurs in the lower stomach which is bypassed with R-en-Y procedure; monitor iron levels; gluconate salt may be better than sulfate
 calcium and vitamin D:  calcium citrate preferred salt for supplementation
 |  | Definition 
 
        | vitamin and mineral deficiencies that may result from gastric bypass |  | 
        |  |